<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR28">
 <label>28.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Assouline</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Culjkovic</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Cocolakis</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Rousseau</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Beslu</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Amri</surname>
    <given-names>A</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin</article-title>
  <source>Blood</source>
  <year>2009</year>
  <volume>114</volume>
  <issue>2</issue>
  <fpage>257</fpage>
  <lpage>60</lpage>
  <pub-id pub-id-type="doi">10.1182/blood-2009-02-205153</pub-id>
  <?supplied-pmid 19433856?>
  <pub-id pub-id-type="pmid">19433856</pub-id>
 </element-citation>
</ref>
